Angiogenesis and tumor expansion are associated with extracellular matrix remodeling and involve various proteases such as the plasminogen (Plg)/ plasminogen activator (PA) system. Recently, several experimental data have implicated the plasminogen activator inhibitor-1 (PAI-1) in tumor angiogenesis in murine systems. However, little is known about PAI-1 functions in human skin carcinoma progression. By generating immunodeficient mice (in Rag-1 À/À or nude background) deleted for PAI-1 gene (PAI-1 À/À ), we have
Introduction
The plasminogen (Plg)/plasminogen activator (PA) system has been implicated in tissue remodelings associated with both physiological and pathologic processes such as wound healing, mammary gland involution, angiogenesis, and cancer invasion. Serine proteases of the PA system are produced both by stromal and neoplastic cells [1, 2] . The PA system is composed of several protein members: 1) Plg, an inactive proenzyme; 2) urokinase PA (uPA) and 3) tissuetype PA (tPA), two serine proteinases able to convert Plg into plasmin; 4) uPA receptor (uPAR); and 5) plasminogen activator inhibitors type I and type II (PAI-1 and PAI-2). These extracellular proteases have multiple functions. Besides their roles in extracellular matrix (ECM) degradation and remodeling, they may also influence the degradation and/or bioavailability of chemokines, cytokines, or their receptors [3] [4] [5] . PAI-1 is a multifunctional glycoprotein containing two active segments. One segment controls matrix proteolysis by inhibiting the conversion of Plg into plasmin by uPA and tPA. The other segment plays a role during cellular adhesion and migration by blocking interaction between vitronectin and different cell surface -associated molecules such as uPA/uPAR complex and integrins (for review, see Refs. [6, 7] ).
Based on extensive clinical and experimental studies, the role of the PA system in cancer progression is now well documented [8 -12] . However, the mechanisms by which the multifunctional PA system promotes malignant progression are still not fully understood. In particular, the role of PAI-1, which has been considered for a long time as a cancer inhibitor, is still the object of a debate. The initially unexpected findings that high PAI-1 levels have a prognostic impact of poor survival for patients suffering from a variety of different cancers raised questions on the functions of PAI-1 [9, 13] . In this context, the surprising proangiogenic function of PAI-1 evidenced by transplanting murine tumor cells into PAI-1 -deficient (PAI-1 À/À ) mice has shed some lights on these paradoxic clinical data [14, 15] . Furthermore, controversial data have been reported on the impact of genetic alterations in PAI-1 levels on tumor progression. One study concluded that neither PAI-1 deficiency nor PAI-1 overexpression affects tumor invasion and metastases of B16 melanoma cells [16] . Recently, lack of spontaneous phenotype in PAI-1 -deficient mice was found consistent with the observation that spontaneous transgenic breast cancer was unaffected by PAI-1 deficiency [17] . In a sarcoma model, both uPA and tPA appeared more crucial for tumor growth than PAI-1 [11] .
Altogether, these findings suggest that the tumorpromoting effects of PAI-1 may be dependent on the tumor type, the site of its production (tumor cells versus host cells), and the stage of the cancer progression. Until now, all studies investigating the impact of PAI-1 deficiency on tumor growth have been performed by transplanting murine tumor cells into syngeneic mice, or by interbreeding PAI-1 -deficient mice with transgenic mice developing oncogenedriven tumors. However, up to now, no information is available regarding the putative role of PAI-1 in human skin or cervical carcinoma progression. To address this question, we have generated immunodeficient PAI-1 knockout mice in two different genetic backgrounds [nude or recombination activating gene-1 (Rag-1) -deficient mice]. Human malignant cervical keratinocytes and human HaCaT-Ras skin carcinoma cells displaying different invasive potentials have been transplanted on a collagen matrix or subcutaneously injected into these mice. In the present study, we demonstrate that PAI-1 is an essential factor of the host microenvironment, promoting early steps of skin carcinoma progression.
Materials and Methods

Genetically Modified Mice
PAI-1 -deficient mice (PAI-1 
Cell Lines and Culture
The malignant HaCaT II-4 clone was derived from human HaCaT keratinocytes after transfection with the mutated val-12-Harvey-Ras oncogene (HaCaT-Ras cells) [18] . HaCaT A5-RT3 clone was established by recultivation in vitro of subcutaneous tumors derived from HaCaT-Ras cells and retransplanted three times in vivo. These two cell lines with HaCaT II-4 (forming well differentiated SCCs) and HaCaT A5-RT3 (growing to poorly differentiated SCCs with local lymph node metastases) display different tumorigenic potentials [19] . The Caski cell line is an HPV16-transformed cervical cell line [20] .
Malignant HaCaT cells were cultivated in modified Eagle's medium containing a four-fold concentration of essential amino acids and vitamins (GIBCO BRL, Paisley, UK), 10% fetal bovine serum (FBS) (GIBCO BRL), penicillin (100 U/ml), and streptomycin (100 mg/ml). The growth medium used for CasKi cells was a 1:3 mixture of Ham's F12/ Dulbecco's modified Eagle's medium (GIBCO BRL), supplemented with 0.4 mg/ml hydrocortisone (Sigma Chemical Co., St Louis, MO), 2 ng/ml epidermal growth factor (Sigma), 10% FBS (GIBCO BRL), 2 mM L-glutamine (GIBCO BRL), 1 mM sodium pyruvate (GIBCO BRL), penicillin (100 U/ml), streptomycin (100 mg/ml) (GIBCO BRL), 5 mg/ml insulin (Sigma), 20 mg/ml adenine (Sigma), 5 mg/ml human transferrin (Sigma), and 15 Â 10 À4 mg/ml 3,3V,5-triiodo-L-thyronine (Sigma). Cells were maintained in a humidified incubator at 37jC with 5% CO 2 . For transplantation assay, cells (2 Â 10 5 ) were plated on a collagen gel (4 mg/ml type I collagen isolated from rat tail tendons) inserted in Teflon rings (Renner GmbH, Darmstadt, Germany) and maintained in culture for 1 day before grafting in mice.
Reverse Transcriptase PCR Analysis Total RNA from HaCaT II-4 and HaCaT A5-RT3 cells was extracted using the High Pure RNA isolation kit (Roche Diagnostics, Mannheim, Germany). RT-PCR amplification was performed using the GeneAmp Thermostable rTth reverse transcriptase RNA PCR kit (Perkin Elmer Life Sciences, Boston, MA), specific pairs of primers (5 pmol each) (Table 1) , and 10 ng of total RNA per 25 ml of reaction mixture (final volume). Reverse transcription was performed at 70jC for 15 minutes. For uPA and PAI-1 transcripts, PCR amplification was run as follows: 15 seconds at 94jC, 20 seconds at 68jC, 10 seconds at 72jC (number of cycles as indicated in Table 1 ), followed by a final 2-minute extension step at 72jC. Other cycling conditions are the followings: 20 seconds at 94jC, 30 seconds at 64jC, 20 seconds at 72jC for tPA, a V and b 3 integrin; and 20 seconds at 94jC, 30 seconds at 60jC, and 20 seconds at 72jC for uPAR and 28S. RT-PCR products were resolved on 10% polyacrylamide gels and analysed using a Fluor-S MultiImager (Bio-Rad, Hercules, CA) after staining with Gelstar dye (FMC BioProducts, Heidelberg, Germany). The selected primer pairs are described in Table 1 .
Enzymatic Assay
HaCaT II-4 and HaCaT A5-RT3 cells were plated at 10 5 cells/well in a 12-well culture plate. After 2 days of culture, cells were rinsed twice with PBS and left in serumfree medium with or without Plg (5 mg/ml; Roche Diagnostics), amiloride, a specific uPA inhibitor (200 mg/ml; Sigma), or a 2 -antiplasmin (3 mg/ml; Sigma). After 24 hours of incubation time, the conditioned media were harvested, centrifuged for 5 minutes at 5Â10 3 g, and then concentrated 10-fold by centrifugation (Amicon Ultra-4 10 4 MW; Millipore, Bedford, MA). Fifty microliters of 10-fold concentrated conditioned media was incubated in 50 mM Tris/HCl, pH 7.4, 100 mM NaCl, 0.01% Tween-20, and 100 mM H-Ala-PheLys-AMC (Bachem, Weil am Rhein, Germany), a fluorogenic plasmin substrate, for 200 seconds at 37jC. Fluorescence was measured in a Microplate Fluorometer (SpectraMax GeminiXS; Molecular Devices, Bedford, MA) at 380 nm (excitation) and 460 nm (emission). Results are expressed as fluorescent arbitrary unit normalized to cell DNA content.
Transplantation Assay in Mice
The cell-coated collagen gels were covered with a silicone transplantation chamber (Renner GmbH) and implanted in toto onto the dorsal muscle fascia of mice as described previously [14, 21] . Three weeks later, transplants were resected, embedded in Tissue Tek (Miles Laboratories, Inc., Naperville, IL), and frozen in liquid nitrogen for cryostat sectioning.
In all assays, the take rate and growth of transplants were verified by classic histology, and some samples were not taken into account. The exclusion criteria were the loss of transplantation chamber, the absence of cells on top of the collagen gel, and the failure of collagen gel adherence onto the host tissue with the consequence of poor cell growth. Based on the two latter parameters, 11% of samples resected from WT mice and 35% of samples resected from PAI-1 À/À mice were excluded (in both immunodeficient backgrounds). These differences reflect the lower remodeling and infiltration of the collagen gel by host cells in PAI-1 À/À mice. Chambers were lost in 7% of WT mice and
Subcutaneous Injection
Cells were inoculated subcutaneously (2 Â 10 6 cells in 200 ml of culture medium per site) into each flank of the animals. Tumor incidence was defined as the percentage of mice presenting a tumor having a volume of at least 50 mm 3 . Immunofluorescence Staining Cryostat sections (6 mm thick) were fixed in acetone at À20jC and 80% methanol at 4jC for 10 minutes, permeabilised in 1% Triton X-100 for 10 minutes, and then incubated with the primary antibodies (Abs). Abs against fibrinogen (goat antimouse) and against VEGF (rabbit antihuman) were purchased from Nordic Immunology (Tilburg, The Netherlands) and Santa Cruz Biotechnology (Santa Cruz, CA), respectively. For double immunofluorescence labeling studies, sections were first incubated for 2 hours at 37jC with the two primary Abs: anti -type IV collagen Ab (guinea pig polyclonal Ab) [22] and anticytokeratin Ab (rabbit polyclonal Ab, diluted 1/200, catalog no. Z0622; Dako, Glostrup, Denmark). The sections were washed in PBS (3 Â 10 minutes) before the incubation with appropriate secondary Abs conjugated to fluorescein -isothiocyanate (FITC) or tetramethyl-rhodamine isothiocyanate (TRITC): goat antiguinea pig IgG (diluted 1/100; ICN Costa Mesa, CA) and monoclonal antirabbit Abs (diluted 1/40; Dako) were applied for 30 minutes at room temperature. The sections were washed three times in PBS for 10 minutes each and coverslips were mounted with Aqua Polymount (Polysciences, Warrington, FL). The specific labeling was observed using an inverted microscope equipped with epifluorescence optics.
The assessment of apoptotic cell death was performed by detecting DNA strand breaks by the terminal deoxynucleotidyl transferase (TdT) -mediated dUTP nick-end labeling (TUNEL) method. Cryostat sections fixed in 4% paraformaldehyde for 20 minutes and in methanol for 5 minutes were stained for apoptosis following the manufacturer's instructions (Roche Diagnostics).
Morphometric Analysis of Angiogenesis and Tumor Cell Invasion
Morphometric assessment of angiogenesis was scored as previously described [23] . A score of (À) means that vessels were undetected in the collagen gel. When blood vessels infiltrate the collagen gel and get into close contact with the malignant epithelial layer, a score of (++) is assigned. A score of (+++) indicates that vessels infiltrated the tumor parenchyma so that invasive epithelial tumor sprouts and vessels are intermingled. Morphometric measurements of tumor cell invasion (average distance of invasion) were performed by using a computer-assisted image analysis system (Quantimet 600 imaging; Leica, Van Hopplynus, Brussels, Belgium). The depth of tumor invasion was determined by measuring the distance between the top of the tumor cell layer and the deepest tumor sprouts [24] . An average distance of invasion was calculated from at least 10 measurements per tumor section.
Statistical Analysis
DATA were analyzed on a computer (GraphPad Prism). The chi-square analysis was used to determine whether there were significant differences in angiogenesis scores between control and genetically modified mice. Quantification results of tumor invasion were statistically analysed using two-tailed Student's t test. Tumor incidence data were analysed with the log rank test. For all experimental conditions, P < .05 was considered as significant.
Results
Tumor Cell Transplantation Into PAI-1 À/À and WT
Nude Mice
The invasive and angiogenic phenotypes of two malignant human cutaneous keratinocytes (HaCaT II-4 and HaCaT A5-RT3) were compared in the surface transplantation assay. We first compared the production of various components of the Plg/plasmin cascade in these two cell lines. An RT-PCR analysis revealed that these cells expressed the different components of the PA system (uPA, uPAR, and PAI-1) at similar levels ( Figure 1 ). Low levels of tPA mRNA were detected in both cell lines (Figure 1 ). To determine PA activities, hydrolysis of plasmin fluorogenic substrate was quantified in the medium conditioned by cells. Addition of exogenous Plg led to a strong hydrolysis of the plasmin substrate, which was completely inhibited by a 2 -antiplasmin. The plasmin activity observed on Plg addition was similar in medium conditioned by HaCaT II-4 (fluorescent arbitrary unit/mg DNA = 416.8 ± 36.1) and HaCaT A5-RT3 (fluorescent arbitrary unit/mg DNA = 357 ± 56.7) (P > .05). A 70% reduction of plasmin activity was observed in both conditioned media after addition of amiloride, an uPA inhibitor (fluorescent arbitrary unit/mg DNA = 124.4 ± 20.7 and 113.9 ± 21.7 for HaCaT II-4 and HaCaT A5-RT3, respectively) (P < .01). This demonstrates that Plg-to-plasmin conversion is mainly mediated by uPA in both cell types. Similar amounts of PAI-1 were produced by both cell lines as assessed by ELISA (3.2 and 3.4 ng/ml for HaCaT II-4 and HaCaT A5-RT3, respectively). Because PAI-1 function may be related to its capacity to interact with a V b 3 integrin, the expression of these two integrin subunits was analyzed by RT-PCR (Figure 1 ). Although both cell lines produced the a V subunit at similar extent, they did not express the b 3 subunit (Figure 1 ).
After this expression profiling analysis, cells cultured on a collagen gel were implanted onto the dorsal muscle fascia of WT and PAI-1 À/À nude mice. Such a grafting in WT mice led to a remodeling of the collagen matrix, infiltration by hostderived cells, and a progressive replacement by a highly vascularized granulation tissue [14, 25] . Three weeks after grafting into WT mice, both cell types formed a multilayered, poorly organized epithelium infiltrated by stromal strands containing capillaries (Figure 2A ). In sharp contrast, when HaCaT A5-RT3 or HaCaT II-4 cells were implanted into PAI-1 -deficient mice, a significant reduction in host connective tissue formation and in tumor growth and invasion was observed. As a consequence, most of the collagen matrix persisted below the stratified epithelial layers (Figure 2A ). Cancer invasion was determined by measuring the maximal depth of penetration of individual tumor sprouts and by calculating the average distance of invasion. Both HaCaT II-4 and A5-RT3 penetrated more deeply into WT host tissue (231.7 ± 15.97 mm and 585.4 ± 109.8 mm , respectively) than into PAI-1 -deficient tissue (103.2 ± 7.72 mm and 210.6 ± 53.82 mm, respectively) (P < .02) (Figure 3, a and b) .
Tumor angiogenesis was visualized after staining for collagen type IV to delineate capillary basement membrane 
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( Figure 4A ) or for CD31/PECAM (data not shown) and semiquantitatively scored ( Figure 5 ). Whereas vessels had reached the epithelial -stromal border and had penetrated the tumor parenchyma in wild-type animals, they stayed apart in PAI-1 -deficient mice separated from the epithelium by the remnant collagen matrix. In accordance with their more aggressive phenotype, about 70% of WT mice grafted with HaCaT A5-RT3 cells were scored as (+++) (Figure 5b ), whereas all HaCaT II-4 tumors were scored as (++) in WT mice (Figure 5a ). After transplantation into PAI-1 À/À nude mice, a reduction of tumor vascularization was detected for both cell types. In the absence of host PAI-1, none of the HaCaT A5-RT3 tumors was scored (+++) and 50% of samples were scored (À) and (++) (P < .01) (Figure 5b) . Most of the HaCaT II-4 tumors (63%) were scored (À) (P < .01) (Figure 5a ). Therefore, PAI-1 À/À mice exhibited significantly reduced tumor invasion and vascularization for both squamous carcinoma cells in comparison to WT mice. To determine whether the tumor-promoting effect of PAI-1 is specific to the type of tumor cell used, the behavior of malignant human cervical keratinocytes (Caski cells) was investigated (Figures 2A and 4A) . Tumor tissues were developed, exhibiting about the same thickness (204.9 ± 37.41 mm in PAI-1 À/À vs 246.7 ± 20.05 mm in WT mice; P > .05) although without pronounced invasion and were vascularized to a similar degree (score ++) in both genotypes (Figures 3c and 5c) . Vascularization, however, was more pronounced at the tumor border in WT than in PAI-1 -deficient animals.
Tumor 
Immunohistochemical Analysis of Tumor Transplants
We carried out an immunohistochemical analysis of tumors transplanted into PAI-1 -proficient or -deficient mice, in both genetic backgrounds (nude or Rag-1
À/À
). We first investigated the deposition of fibrin as an end-point of a plasmin-mediated fibrinolysis and as a provisional matrix for cell migration and invasion. Lack of host PAI-1 did not lead to any obvious modification of fibrin(ogen) deposition, suggesting that fibrinolysis was not changed in the absence of PAI-1 (data not shown). Although a decrease of VEGF production has been reported in the absence of PAI-1 [15, 26] , no difference of VEGF staining was evidenced in our transplantation system (data not shown). Similarly, TUNEL stainings for apoptotic cells indicated that the extent of apoptosis was always low in the cancer cell layers, in endothelial cells of blood vessels associated to the stromal strands of WT tumors, or in blood vessels remaining below the collagen gel in PAI-1 À/À mice (data not shown).
Subcutaneous Growth of Cells Injected
The in vivo tumorigenicity of the two HaCaT variants was next evaluated by subcutaneous inoculation into PAI-1 À/À mice and their control counterpart, in both nude and Rag-1 À/À backgrounds. As shown in Figure 6 , the tumor incidence in nude PAI-1 À/À mice injected with HaCaT II-4 was significantly decreased as compared to that observed in WT mice (P < .05). Indeed, 38 days after cell injection, HaCaT II-4 cells gave rise to 100% tumors in WT mice and 62.5% in PAI-1 -deficient mice ( Figure 6A ). A reduction of tumor incidence was also observed in the Rag 1 À/À background ( Figure 6B ). In sharp contrast, within 2 or 3 weeks, the more aggressive HaCaT A5-RT3 cells gave rise to 80% to 100% of tumors in mice regardless of PAI-1 status and in both nude and Rag-1 backgrounds ( Figure 6 ). To better define the process leading to a reduction of HaCaT II-4 tumor incidence in PAI-1 À/À mice, tumor growth was also evaluated. We observed that once the tumors were established, the increase of tumor volumes was identical in both genotypes and was not dependent on the expression levels of host PAI-1 (data not shown). These data suggest that PAI-1 displays a growth-promoting effect for poorly aggressive cancer cells during early stages of tumor growth, but is dispensable when the tumor is undergoing expansion. In the case of more aggressive tumors (HaCaT A5-RT3 cells), consistent with the effect on tumor incidence (Figure 6 ), the growth rate was similar in the absence or presence of host PAI-1 (data not shown).
Discussion
The onset of invasion represents an early step in the conversion of a carcinoma in situ to a malignant squamous cell carcinoma (SCC) with the capacity to spread and to eventually metastasize. Angiogenesis and tumor vascularization appear as a crucial prerequisite for invasion [21, 27] . Angiogenesis involves a tightly controlled orchestration of complex interactions between tumor cells, host cells, soluble factors, and ECM components that lead to the formation of new blood vessels. The specific functions of the in vivo microenvironment in controlling the invasive and angiogenic phenotypes of tumor cells are still poorly understood. However, the recent generation of targeted gene -deficient mice has been helpful to identify individual genes playing a key role during tumor growth and vascularization. In this context, PAI-1 hasbeen identified as a crucial element of the Plg/PA system controlling in vivo tumor angiogenesis [14, 15, 23] . and their corresponding WT) in both immunodeficient genetic backgrounds demonstrated the dramatic effect of host PAI-1 absence on SCC growth and vascularization. The present study provides evidence that PAI-1 in these models is a crucial determinant of tumor microenvironment in regulating and enhancing early stages of human skin carcinoma invasion.
When two different human cell lines were transplanted as a precultured epithelium on a collagen gel (surface transplantation system), both tumor invasion and vascularization were reduced in PAI-1 -deficient mice. In accordance with their more aggressive phenotype, HaCaT A5-RT3 transplants were much more vascularized (score +++) in WT mice than HaCaT II-4 transplants. A significant reduction of the invasive and angiogenic phenotypes of both HaCaT II-4 and HaCaT A5-RT-3 cells was determined by objective morphometric quantification. This important effect of PAI-1 deficiency on tumor progression emphasizes the key role played by host cells during this process. With low tumor cell numbers, PAI-1 produced by neoplastic cells is not sufficient to circumvent host deficiency. Indeed, by transfecting malignant keratinocytes with PAI-1 cDNA, we previously showed that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host tissue [24] . The present data provide the first experimental evidence for a role of stromal PAI-1 in human skin cancer invasion and vascularization.
Although the precise mechanism of PAI-1 action is not well understood, several lines of evidence indicate that PAI-1 effects result from a tight control of extracellular proteolysis and/or a regulation of cell detachment and migration by its interaction with vitronectin and integrins [28, 29] . By using adenoviral delivery of mutated forms of PAI-1, we have previously demonstrated that PAI-1 facilitates tumor angiogenesis [23, 30] or laser-induced choroidal angiogenesis [31] by inhibiting proteolytic activity rather than by interacting with vitronectin. In the present study, the lack of b 3 integrin subunit expression by the cells used is consistent with a PAI-1 -mediated regulation of angiogenesis without involvement of integrins. The requirement of a good balance between PA and PAI-1 is supported by recent data showing that the proangiogenic and antiangiogenic effects of PAI-1 are dose-dependent [24, 30, 32, 33] . In other models, PAI-1 effects have been ascribed to both antiprotease and vitronectin-binding functions [28, 34] . Because PAI-1 is a multifunctional molecule, it is likely that its mechanisms of action are dependent on the tumor types and/or on the stage of cancer progression. Host PAI-1 did not affect the extent of apoptosis of tumor cells and/or stromal cells as assessed by TUNEL stainings (data not shown). This is consistent with a previous report of recombinant PAI-1 administration into mice bearing melanomas [33] . In vivo studies have reported a decrease in VEGF expression in the absence of PAI-1 [15, 26] . However, by immunohistochemical analysis, similar VEGF stainings were detected in tumor cell transplants in the absence or presence of PAI-1. We cannot exclude the possibility that VEGF produced by tumor cells can compensate for a putative regulation of stromal VEGF expression in the absence of PAI-1. However, our data are in accordance with the identical levels of both VEGF transcripts and proteins evidenced in aortic endothelial cells isolated from WT and PAI-1 À/À mice [35] . It has been proposed that alterations in the rate of cell proliferation in PAI-1 À/À endothelial cells may affect vessel formation and stability [35] . However, by using the surface transplantation system, similar numbers of vessels were detected below the collagen gels in both WT and PAI-1 À/À mice, thus reflecting an identical angiogenic response induced below the transplant in both genotypes [14] . This suggests that inhibition of angiogenesis is more related to impaired ability of endothelial cells to infiltrate an ECM or the tumor parenchyma rather than to an aberrant proliferation rate. This is consistent with the defective spreading of endothelial cells from aortic fragments issued from PAI-1 À/À mice [30] . The impaired angiogenesis was not related to the use of a collagen type I matrix because tumor cell implantation in the presence of Matrigel led to similar dependency on host PAI-1 [24] . Cells were also subcutaneously inoculated into WT or PAI-1 À/À mice. The lack of PAI-1 significantly reduced the incidence of subcutaneous tumors derived from poorly aggressive HaCaT II-4 cells, but not the incidence of tumors derived from the more aggressive HaCaT A5-RT3 cells. However, in both cases, once implanted, the proliferation rate of tumors was not dependent on the PAI-1 status of host tissue. These data emphasize the importance of PAI-1 in the early steps of cancer progression and confirmed our recent study using murine PDVA cells [24] . A similar observation was already done for stromelysin-3 (MMP-11), which appears to control tumor cell apoptosis [36 -38] . Such a specific effect of PAI-1 in early events of cancer progression rather than during the course of cancer expansion may provide an explanation for some of the apparently contradictory reports in the literature. Also, the number of transplanted/injected tumor cells and their production of tumor cell -derived PAI-1 may account for the differences seen in surface transplants (low cell number) and subcutaneous tumors (10 times higher injected cell number) concerning the effects on tumor growth and invasion. In addition, the absence of PAI-1 effect on the evolution of tumors induced by human cervical CasKi cell transplantation suggests that PAI-1 is not a universal proangiogenic factor and that its effect may be tumor type -dependent or tumor stage -dependent [6] .
In conclusion, our data provide new insights into the function of an individual component of the Plg/PA system, host PAI-1, in specific steps of human cancer implantation. Interestingly, it extends the importance of PAI-1 to human skin carcinomas.
